Top 10 medical innovations for 2022 – Lab + Life Scientist

Cleveland Clinic, a leading global health system, has announced its Top 10 Medical Innovations for 2022. The list of breakthrough technologies was selected by a committee of Cleveland Clinic subject matter experts, led by D Geoffrey Vince, PhD, Executive Director of Innovations and Chair of Biomedical Engineering at Cleveland Clinic.
“At Cleveland Clinic, a shared passion for the delivery of superior care and an embedded culture of innovation foster continuous healthcare improvement dialogue among our clinicians and researchers,” Dr Vince said. “As such, our experts always have their finger on the pulse of new technologies slated to change the face of health care. The Top 10 Medical Innovations program was launched to share their insight with the broader healthcare community, and year after year our professionals continue to successfully predict device, technology, theme and therapy advances.”
Here, in order of anticipated importance, are the Top 10 Medical Innovations for 2022:
Advancements in the generation, purification and cellular delivery of RNA have enabled the development of mRNA vaccines across a broad array of applications, such as cancer and Zika virus infection. The technology is cost-effective, relatively simple to manufacture, and elicits immunity in a novel way. Furthermore, the emergence of the COVID-19 pandemic demonstrated that the world needed rapid development of a vaccine that was deployable around the globe. Because of previous research that laid the groundwork for this technology, an effective COVID-19 vaccine was developed, produced, approved and deployed in less than a year. This landscape-changing technology has the potential to be used to manage some of health care’s most challenging diseases quickly and efficiently.
Each year, more than 200,000 American men receive a diagnosis of prostate cancer — making it the most commonly diagnosed cancer among men in the United States. Accurate imaging is critical for tumour localisation, staging the disease and detecting recurrences. PSMA, an antigen found in high levels on the surface of prostate cancer cells, is a potential biomarker for the disease. PMSA PET scans use a radioactive tracer to attach to PSMA proteins, which are then combined with CT or MRI scans to visualise the location of prostate cancer cells. In 2020, this technology received approval from the US Food and Drug Administration (FDA) based on phase III clinical trials, which showed substantially increased accuracy for detecting prostate cancer metastasis compared to conventional imaging with bone and CT scans. When detected early by PSMA PET scans, recurrent prostate cancer can be treated through a targeted approach with stereotactic body radiation therapy, surgery and/or systemic therapy in a personalised manner.
High levels of blood cholesterol, particularly low-density lipoproteins (LDL-C), are known to be a significant contributor to cardiovascular disease. In 2019, the FDA reviewed the application for inclisiran in treating primary hyperlipidemia in adults who have elevated LDL-C while on a maximally tolerated dose of statin therapy. Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosing (twice per year) and provides effective and sustained LDL-C reduction in conjunction along with statins. Its prolonged effect may help alleviate medication non-compliance, one of the leading causes of failure to lower cholesterol levels. Inclisiran was FDA approved in December 2021 and is widely considered a game changer for heart disease patients.
According to the World Health Organization, around 422 million people worldwide have diabetes, which affects how the body processes food into energy. One potential therapy is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) that aims to control blood sugar. Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal. Additionally, it slows digestion, resulting in individuals remaining full for longer and eating less. Thus far, late phase III clinical trials reveal that the treatment significantly reduces haemoglobin A1C in type 2 diabetes and supports weight loss, making it potentially the most effective therapy for diabetes and obesity yet developed.
Experts believe the rate of postpartum depression could be at least twice as high as what current statistics reveal because many cases go undiagnosed. Currently, counselling and antidepressant medications are the primary treatments but some women do not respond to these therapies. In 2019, the FDA approved an intravenous infusion treatment designed to treat postpartum depression specifically. This novel therapy, administered around the clock for 60 hours, uses a neurosteroid to control the brain’s response to stress.
This treatment design is groundbreaking as it targets the signalling thought to be deficient in hormone-sensitive postpartum depression. Additionally, this treatment appears to show benefits very quickly, while traditional antidepressants typically take two to four weeks to have a significant effect. This rapid treatment option would be a breakthrough for women with this often-overlooked condition.
For decades, clinicians have only been able to treat patients’ hypertrophic cardiomyopathy (HCM) symptoms — using drugs developed to treat other heart conditions — with limited effectiveness. Currently, non-specific medications are prescribed to treat some of the symptoms that HCM shares with other cardiovascular diseases. These therapies include beta-blockers, anti-arrhythmic drugs, calcium channel blockers and anticoagulants. A new treatment, however, works to reduce the root cause of the problem in many patients. A first-in-class medication specifically targets heart muscle to reduce abnormal contractions caused by genetic variants that put the heart into overdrive. By acting specifically on this mechanism in HCM patients, this novel treatment not only improves symptoms and quality of life, but potentially could slow progression of the disease. The FDA has assigned a target action date for this therapy of 28 April 2022. If approved, this would be the first medication explicitly dedicated to treating HCM and providing new hope to patients and physicians.
More than 50% of all menopausal women experience hot flashes, which can persist for an average of seven years. While effective and safe when used appropriately, hormone therapy involves some risk and not all patients are appropriate candidates or ready to try this treatment option. Fortunately, a new group of non-hormonal drugs, called NK3R antagonists, have emerged as a viable alternative to hormone therapy. These drugs disrupt a signalling pathway in the brain that has been linked to the development of hot flashes and have shown promise in clinical trials for relieving moderate to severe menopausal hot flashes as effectively as hormones. While additional studies are needed to fully understand the effectiveness and safety of these new drugs, it is clear that the next generation of non-hormonal treatments for menopausal hot flashes is on the horizon.
Approximately one in 50 Americans, or 5.4 million people, have some form of paralysis. Most patients experience a significant decline in their overall health. Recently, a team has offered new hope for these patients by leveraging implanted brain–computer interface technology to recover lost motor control and enable patients to control digital devices. The technology uses implanted electrodes to collect movement signals from the brain and decode them into movement commands. It has been shown to restore voluntary motor impulses in patients with severe paralysis due to brain, spinal cord, peripheral nerve or muscle dysfunction. While the interface technology is in its infancy, the FDA has designated the implantable a ‘breakthrough device’, reinforcing the need to move this technology to the bedside of patients who need it most.
Sepsis is a severe inflammatory response to infection and a leading cause of hospitalisation and death worldwide. Because septic shock has a very high mortality rate, early diagnosis of sepsis is critical. Diagnosis can be complicated because early symptoms are common across other conditions, and the current standard for diagnosis is non-specific. Artificial intelligence (AI) has surfaced as a new tool that can help rapidly detect sepsis. Using AI algorithms, the tool detects several key risk factors in real time by monitoring patients’ electronic medical records as physicians input information. Flagging high-risk patients can help facilitate early intervention, which can improve outcomes, lower healthcare costs and save lives.
Often referred to as the ‘silent killer’, hypertension, or high blood pressure, usually shows no symptoms while increasing risk for serious health problems, including heart disease, heart failure and stroke. Effective treatment options exist; however, many adults remain unaware that they have hypertension until they experience a significant health crisis. Using machine learning, a type of artificial intelligence, physicians are able to better select more effective medications, medication combinations and dosages to improve control of hypertension. AI also will allow physicians to predict cardiovascular morbidities and enable physicians to focus on interventions before they occur. Predictive analytics equip providers with the key that could open the door to preventing hypertension and many other diseases.
For more information on the annual Top 10 Medical Innovations list, including descriptions, videos and year-by-year comparisons, click here.
Image credit: ©
Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.
Professor Pall (Palli) Thordarson, an award-winning researcher, is set to kickstart RNA…
Researchers have grown synthetic embryo models of mice outside the womb by starting solely with…
Researchers have shown that the loss of the male sex chromosome as many men age causes the heart…
Life Science and Laboratory Decontamination
Sustainability in the Lab Concerns Us All
High-throughput automation and genomics for an antimicrobial resistance surveillance system

EVC endorses fuel efficiency standards
Ecological transformation and the circular economy switch would solve the NSW energy debate
Successful emissions monitoring with CAC GAS Specialty Gases
Automated recycling plant to launch near Brisbane
Climate Bill passes lower house

Safety first: selecting the right encoders for safe motion control
SA manufacturing companies expand their expertise to space
BHP in partnership to harness wind-assisted propulsion
Clean energy conference to tackle renewables, hydrogen
Business booming for KUKA despite difficult world situation

 Supporting clinician wellbeing: caring for the healthcare workforce
Plants pilot study to boost hospital staff wellbeing
Tiny bed sensors could put an end to hospital pressure sores
HIV advocates translate academic research into 'plain speak'
Nurses to convene on Darwin for national conference
Westwick-Farrow Media
Locked Bag 2226
North Ryde BC NSW 1670
ABN: 22 152 305 336
Email Us
LabOnline has an editorial mix of business news, research and funding updates, industry comment, feature articles, conference previews, case studies and succinct new product items, making it a ‘must read’ for industry leaders.
Membership is FREE to qualified industry professionals across Australia.